HC Wainwright Has Negative Outlook for ANIP FY2027 Earnings

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Research analysts at HC Wainwright decreased their FY2027 EPS estimates for ANI Pharmaceuticals in a research note issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the specialty pharmaceutical company will post earnings per share of $8.09 for the year, down from their previous estimate of $8.11. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $8.03 per share.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the firm posted $1.80 earnings per share. The business’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Stock Down 0.7%

Shares of ANI Pharmaceuticals stock opened at $76.00 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals has a 1-year low of $70.15 and a 1-year high of $99.50. The business’s fifty day moving average price is $80.73 and its two-hundred day moving average price is $78.99. The company has a market capitalization of $1.75 billion, a P/E ratio of 16.38 and a beta of 0.44.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the transaction, the senior vice president directly owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 2,850 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the transaction, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. This represents a 1.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 18,987 shares of company stock worth $1,546,405. 8.10% of the stock is owned by insiders.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ANIP. Vanguard Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the last quarter. State Street Corp grew its position in ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG increased its holdings in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in ANI Pharmaceuticals by 19.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after acquiring an additional 91,153 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after acquiring an additional 43,523 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.